Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

American Urogynecologic Society Systematic Review

Microscopic Hematuria as a Screening Tool for Urologic Malignancies in Women

Jeppson, Peter C. MD*; Jakus-Waldman, Sharon MD, MPH; Yazdany, Tajnoos MD; Schimpf, Megan O. MD§; Ferzandi, Tanaz R. MD, MBA; Yurteri-Kaplan, Ladin A. MD, MS; Knoepp, Leise MD, MPH**; Mamik, Mamta MD††; Resnick, Helaine E. PhD, MPH‡‡; Ward, Renee M. MD§§ for the American Urogynecologic Society Systematic Review Committee

Female Pelvic Medicine & Reconstructive Surgery: April 12, 2019 - Volume Publish Ahead of Print - Issue - p
doi: 10.1097/SPV.0000000000000726
Original Article: PDF Only

Introduction Most causes of microscopic hematuria (MH) are benign but may indicate an underlying malignancy. Current MH evaluation guidelines are reflective of male urologic malignancy risks. The objective of this systematic review was to evaluate whether the finding of MH predicts subsequent urologic malignancy in women.

Methods MEDLINE was searched between January 1990 and June 8, 2018. The positive predictive value (PPV) of MH as a screening tool for urologic malignancy was calculated for each study individually and collectively. The pooled relative risk of urologic malignancy associated with MH was calculated.

Results Seventeen studies were included. Eight studies included only women. In total, 300 urinary tract cancers were identified in 110,179 women with MH. The PPV of MH as a screening tool for cancer ranged from approximately 0.6% to 2.8%; confidence intervals (CIs) suggested this is a relatively unstable performance indicator because of small sample sizes. Average PPV across all studies was 2.13%, but the weighted average PPV was 0.24%. The risk of urologic malignancies among women with relative those without MH was 2.01 (95% CI, 1.61–2.51). Based on these limited data, we estimate that 859 (95% CI, 654–1250) women with MH would require complete evaluation to identify 1 urinary tract malignancy.

Conclusions A very small proportion of women with MH are likely to have a urologic malignancy. Approximately 859 women require full screening to identify 1 malignancy. Current evidence is limited, and further studies, specifically in women, are needed.

From the *University of New Mexico, Albuquerque, NM;

Kaiser Permanente Downey, Downey, CA; and

Harbor-UCLA Medical Center, Torrance, CA;

§University of Michigan, Ann Arbor, MI;

Tufts Medical Center, Boston, MA;

Columbia University Medical Center, New York, NY;

**Ochsner Medical Center, New Orleans, LA;

††Icahn School of Medicine at Mount Sinai, New York, NY;

‡‡Resnick, Chodorow and Associates, LLC, Silver Spring, MD; and

§§Vanderbilt University Medical Center, Nashville, TN.

Correspondence: Peter C. Jeppson, MD, Division of Urogynecology, University of New Mexico, 1 University of New Mexico, MSC 10 5580, Albuquerque, NM 87131. E-mail:

The authors have declared they have no conflicts of interest.

This document was developed by the American Urogynecologic Society. This document reflects clinical and scientific advances and expert opinion as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Its content is not intended to be a substitute for professional medical judgment, diagnosis, or treatment. The ultimate judgment regarding any specific procedure or treatment is to be made by the physician and patient in light of all circumstances presented by the patient.

Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.